AU594167B2 - A crystalline hydrate of oral cephalosporin and its composition - Google Patents

A crystalline hydrate of oral cephalosporin and its composition Download PDF

Info

Publication number
AU594167B2
AU594167B2 AU75040/87A AU7504087A AU594167B2 AU 594167 B2 AU594167 B2 AU 594167B2 AU 75040/87 A AU75040/87 A AU 75040/87A AU 7504087 A AU7504087 A AU 7504087A AU 594167 B2 AU594167 B2 AU 594167B2
Authority
AU
Australia
Prior art keywords
drying
hydrate
gelatin
capsule
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU75040/87A
Other languages
English (en)
Other versions
AU7504087A (en
Inventor
Yoshio Hamashima
Kyozo Kawata
Kyoji Minami
Teruo Sakamoto
Yusuke Suzuki
Toyohiko Takeda
Masanori Tujikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61156954A external-priority patent/JP2544113B2/ja
Priority claimed from JP21626086A external-priority patent/JPH0717651B2/ja
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU7504087A publication Critical patent/AU7504087A/en
Application granted granted Critical
Publication of AU594167B2 publication Critical patent/AU594167B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
AU75040/87A 1986-07-02 1987-07-02 A crystalline hydrate of oral cephalosporin and its composition Expired AU594167B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP61156954A JP2544113B2 (ja) 1986-07-02 1986-07-02 安定なカプセル製剤
JP61-156954 1986-07-02
JP61-216260 1986-09-12
JP21626086A JPH0717651B2 (ja) 1986-09-12 1986-09-12 経口投与用セフアロスポリン水和物結晶

Publications (2)

Publication Number Publication Date
AU7504087A AU7504087A (en) 1988-01-07
AU594167B2 true AU594167B2 (en) 1990-03-01

Family

ID=26484565

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75040/87A Expired AU594167B2 (en) 1986-07-02 1987-07-02 A crystalline hydrate of oral cephalosporin and its composition

Country Status (27)

Country Link
US (2) US4812561A (enExample)
KR (1) KR950005302B1 (enExample)
CN (1) CN1015106B (enExample)
AR (1) AR243893A1 (enExample)
AT (1) AT392472B (enExample)
AU (1) AU594167B2 (enExample)
BE (1) BE1001691A4 (enExample)
CA (1) CA1283405C (enExample)
CH (1) CH672788A5 (enExample)
DE (1) DE3721913A1 (enExample)
DK (1) DK161080C (enExample)
ES (2) ES2004952A6 (enExample)
FI (1) FI89052C (enExample)
FR (1) FR2601014B1 (enExample)
GB (1) GB2192183B (enExample)
GR (1) GR871014B (enExample)
HK (1) HK47893A (enExample)
HU (1) HU200777B (enExample)
IE (1) IE59613B1 (enExample)
IL (1) IL83059A (enExample)
IT (1) IT1211469B (enExample)
NL (1) NL193136C (enExample)
NO (1) NO170889C (enExample)
NZ (1) NZ220764A (enExample)
PL (1) PL159180B1 (enExample)
RU (1) RU1829932C (enExample)
SE (1) SE466257B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
AU674516B2 (en) * 1992-04-30 1997-01-02 Schering Corporation Stable hydrated cephalosporin dry powder for oral suspension formulation
CN1307211C (zh) * 1998-10-27 2007-03-28 伊斯曼化学公司 烯烃聚合方法,新型聚乙烯以及由其制造的薄膜和制品
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AT412213B (de) * 2000-05-30 2004-11-25 Sandoz Ag Verfahren zur trocknung von amoxicillin oder amoxicillin-hältigen, oralen, festen pharmazeutischen zusammensetzungen unter verwendung eines gases mit einer definierten gasfeuchte
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
CA2533358C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
EP1771158A4 (en) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
CA2629244C (en) 2005-11-11 2014-08-05 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
MX2009006878A (es) * 2006-12-22 2009-07-07 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
US8268803B2 (en) 2006-12-22 2012-09-18 Merck Sharp & Dohme Corp. 5, 6-ring annulated indole derivatives and use thereof
KR20090094154A (ko) 2006-12-22 2009-09-03 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
TW200924751A (en) * 2007-08-29 2009-06-16 Schering Corp 2,3-substituted indole derivatives and methods of use thereof
KR20100065167A (ko) 2007-08-29 2010-06-15 쉐링 코포레이션 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체
CN101821252A (zh) * 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
MX2010005355A (es) * 2007-11-16 2010-06-02 Schering Corp Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
MX2010013630A (es) * 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
DK2451445T3 (da) 2009-07-06 2019-06-24 Boehringer Ingelheim Int Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
BR112012022125A2 (pt) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
EP2566449B1 (en) 2010-05-04 2014-10-08 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
JP2013541499A (ja) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
WO2013151518A1 (en) * 2012-04-04 2013-10-10 Mahmut Bilgic Capsule formulations comprising ceftibuten
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103948932B (zh) * 2014-04-17 2016-03-16 海南日中天制药有限公司 一种头孢克肟组合物及其制备方法
EP3031450A1 (en) 2014-12-12 2016-06-15 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten capsule compositions
US11117909B2 (en) 2016-05-13 2021-09-14 Aeromics, Inc. Crystals
CN106397454B (zh) * 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
CN106432270A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106397457A (zh) * 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106432272A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432271A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
JP2024524372A (ja) * 2021-07-01 2024-07-05 キューペックス バイオファーマ， インコーポレイテッド セフチブテンの結晶形態

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819620A (en) * 1972-06-01 1974-06-25 Squibb & Sons Inc 7-(d-alpha-amino-1,4-cyclohexadien-1-ylacet-amido)desacetoxycephalosporanic acid dihydrate
JPS5726692A (en) * 1980-07-22 1982-02-12 Fujisawa Pharmaceut Co Ltd Preparation of stable crystal of salt of ceftizoxime
DE3037997A1 (de) * 1980-10-08 1982-05-13 Bayer Ag (beta) -lactamantibiotika, verfahren zu deren herstellung sowie sie enthaltende mittel
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins

Also Published As

Publication number Publication date
KR950005302B1 (ko) 1995-05-23
GB2192183A (en) 1988-01-06
DK336487D0 (da) 1987-06-30
AT392472B (de) 1991-04-10
ATA165887A (de) 1990-09-15
FI89052B (fi) 1993-04-30
AU7504087A (en) 1988-01-07
NL193136B (nl) 1998-08-03
IE59613B1 (en) 1994-03-09
PL159180B1 (pl) 1992-11-30
FI89052C (fi) 1993-08-10
HU200777B (en) 1990-08-28
US4812561A (en) 1989-03-14
BE1001691A4 (fr) 1990-02-13
GB2192183B (en) 1990-05-16
CN87105009A (zh) 1988-03-23
FI872903L (fi) 1988-01-03
US4933443A (en) 1990-06-12
KR880001670A (ko) 1988-04-26
ES2008759A6 (es) 1989-08-01
IE871738L (en) 1988-01-02
IL83059A0 (en) 1987-12-31
FR2601014B1 (fr) 1990-09-14
RU1829932C (ru) 1993-07-23
HUT44257A (en) 1988-02-29
DE3721913A1 (de) 1988-01-07
SE8702705D0 (sv) 1987-06-30
ES2004952A6 (es) 1989-02-16
CH672788A5 (enExample) 1989-12-29
FR2601014A1 (fr) 1988-01-08
NL193136C (nl) 1998-12-04
NO170889C (no) 1992-12-23
GR871014B (en) 1987-11-02
PL266567A1 (en) 1988-07-21
NZ220764A (en) 1989-09-27
DK336487A (da) 1988-01-03
FI872903A0 (fi) 1987-07-01
DK161080B (da) 1991-05-27
AR243893A1 (es) 1993-09-30
IL83059A (en) 1992-03-29
SE466257B (sv) 1992-01-20
IT8767566A0 (it) 1987-07-01
NL8701507A (nl) 1988-02-01
IT1211469B (it) 1989-11-03
HK47893A (en) 1993-05-27
NO872729L (no) 1988-01-04
CA1283405C (en) 1991-04-23
CN1015106B (zh) 1991-12-18
GB8715064D0 (en) 1987-08-05
NO170889B (no) 1992-09-14
NO872729D0 (no) 1987-06-30
DK161080C (da) 1991-11-11
SE8702705L (sv) 1988-01-03

Similar Documents

Publication Publication Date Title
AU594167B2 (en) A crystalline hydrate of oral cephalosporin and its composition
US5017380A (en) Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
US20200339600A1 (en) Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximin
CA1190220A (en) Process for the manufacture of highly crystalline sodium cefoperazone
US4866170A (en) Stable hydrate of penicillin derivative
DE3745094B4 (de) Ein kristallines Hydrat der 7ß-[(Z)-2-(2-Aminothiazol-4-yl)-4-carboxybut-2-enoylamino]-3-cephem-4-carbonsäure enthaltende Hartgelatinekapsel-Zusammensetzung
GB1561395A (en) -lactam antibiotic
WO2017140073A1 (zh) 一种采用粒子过程晶体产品分子组装与形态优化技术的头孢硫脒新晶型化合物及制剂
FI95349C (fi) Menetelmä 7 -/(Z)-2-(2-aminotiatsol-4-yyli)-4-karboksibut-2-enoyyliamino/-3-kefeemi-4-karboksyylihappoa sisältävän gelatiinikapselin valmistamiseksi
SU1560057A3 (ru) Способ получени кристаллического тригидрата или дигидрата или их смесей 7 @ -/(Z)-2-(2-аминотиазол-4-ил)-4-карбоксибут-2-еноиламино/-3-цефем-4-карбоновой кислоты
CN1036632C (zh) 含口服头孢菌素结晶性水合物的组合物制法
US20220119410A1 (en) Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximin
AT396652B (de) Verfahren zur herstellung von hartgelatinekapsel-zusammensetzungen
DD276031A5 (de) Verfahren zur herstellung einer hartgelantinekapsel-zusammensetzung eines kristallinen hydrats der 7beta-[(z)-2-(2-aminothiazol-4-yl-)-4-carboxybut-2-enoylamino]-3-cephem-4-carbonsaeure
HU210527A9 (hu) Cefalosporin kristályos hidrátja orális alkalmazáshoz és az ezt tartalmazó készítmény Az átmeneti oltalom az 1-4. és 15-17. igénypontokra vonatkozik.
CN111187285A (zh) 氟氧头孢钠的晶型、制备方法、药物组合物及应用
NO303264B1 (no) FremgangsmÕte for fremstilling av et stabilt kapselpreparat
LV11180B (en) Diamine salts of clavulanic acid

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 20030702 TO 20040120 IN WHICH TO PAY A RENEWAL FEE HAS BEEN LODGED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 20040120